Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: November 2006
-
By Christopher P. Singer — Last week the United States and European Patent Offices announced that the agencies will begin to exchange priority documents in an electronic format. This program will impact applicants that have filed an application with the U.S. or European Patent Offices (a "priority document"), and subsequently wish to file…
-
By Donald Zuhn — In an appeal from a District Court judgment of validity and noninfringement, the Federal Circuit reversed the District Court's finding of validity, holding the asserted claims in U.S. Patent No. 5,990,176 to be anticipated by the disclosure in U.S. Patent No. 5,684,211. The '176 patent relates to degradation-resistant compositions…
-
By Jason Derry– For companies interested in entering the Australian biotechnology industry, the Australian Government has created a new website related to biotechnology regulatory requirements. The website, BioRegs Online (www.bioregs.gov.au), was designed to provide easily accessible information to assist companies in devising plans for developing and marketing biotech products. Specifically, BioRegs Online hopes…
-
By Jason Derry — Can the open source problem-solving model used in the software community work in the world of science? The Harvard Business School has published a very interesting interview on this topic (see "Open Source Science: A New Model for Innovation"). In the interview, Karim R. Lakhani, assistant professor at the…
-
By Jason Derry — The Sino-American Biotechnology and Pharmaceutical Professionals Association (SABPA) is a non-profit organization dedicated to fostering licensing and other partnering relationships among biotechnology and pharmaceutical companies and academia in the United States and China. The SABPA hosts numerous networking events, such as dinners and conferences, to facilitate communication between investors,…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma patent cases. A few interesting cases will be selected for periodic monitoring, providing our readers with an opportunity to follow the progress of these cases. Dusa Pharmaceuticals, Inc. et. al. v. Fronteir Scientific, Inc.1:06-cv-00141;…
-
The Biotechnology Industry Organization (BIO) is hosting the fourth BIO-Asia Partnering Conference in Tokyo on January 29 and 30, 2007. According to BIO’s press release, the conference allows biotech and pharmaceutical companies from Asia, Europe, Australia, and the United States to meet together for the purpose of exploring potential partnering opportunities. The past year’s event…
-
By Jason Derry — NeuroMedix Inc., a biotechnology company seeking therapeutic approaches for treating neuronal diseases, has announced the intent to pursue partners or acquisition possibilities. The company currently has a potential product, Minozac, in pre-clinical studies, and is preparing to submit the Phase I safety application for continuing clinical trial progression. Minozac…
-
By Christopher P. Singer — With the release of EFS-Web 1.1 on October 14, 2006, the USPTO has streamlined the filing of sequence listings for practitioners and patentees. The prior version of EFS-Web was limited because it allowed submission of files in .pdf format only and was not enabled to handle sequence listings,…
-
ESTs Unpatentable for Failure to Satisfy 35 U.S.C. § 101 Where Function of Underlying Gene Is Unknown By Sherri Oslick — In an opinion of great import to biotechnology patent law, the Federal Circuit affirmed the decision of the Board of Patent Appeals that denied a patent to five expressed sequence tags (ESTs)…
Patent Docs 